Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06548360 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
A Phase 3 study of NonSegmental Vitiligo, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06548360 is a Phase 3 study of NonSegmental Vitiligo that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 180 participants, below the 372-participant average among 3 other NonSegmental Vitiligo trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06548360, a Phase 3 study of NonSegmental Vitiligo, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream
- DRUG Vehicle Cream
Study Locations (20)
California
- Axon Clinical Research - Inglewood
- University of California Irvine - Irvine
- Vitiligo & Pigmentation Institute of Southern California - Los Angeles
- Dermatology Research Associates - Los Angeles
- La Universal Research Center, Inc - Los Angeles
- Stanford School of Medicine - Palo Alto
- Empire Clinical Research - Pomona
- Norcal Clinical Research - Rocklin
- Peninsula Research Associates Pra - Rolling Hills Estates
- Integrative Skin Science and Research - Sacramento
- Rady Children'S Hospital-San Diego - San Diego
Arizona
- Phoenix Children'S Hospital - Phoenix
- Omni Dermatology - Phoenix
- Affiliated Dermatology - Scottsdale
- Banner - University Medicine Multispecialty Services Clinic - Tucson
Arkansas
- Premier Dermatology Clinical Trials Institute At Northwest Arkansas - Fayetteville
- Burke Pharmaceutical Research - Hot Springs
Colorado
- Children'S Hospital Colorado - Aurora
- Paradigm Clinical Research Centers, Inc. - Wheat Ridge
Alabama
- University of Alabama At Birmingham-School of Medicine - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2027-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06548360
The ClinicalTrials.gov registry entry for NCT06548360 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 372-participant average among 3 other NonSegmental Vitiligo trials with a reported enrollment target (52% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NonSegmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib Cream is the first listed.
NCT06548360 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06548360 about?
NCT06548360 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo". The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
What is the current status of trial NCT06548360?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-01-24. Estimated completion is 2027-03-13.
What conditions does trial NCT06548360 study?
This clinical trial studies the following conditions: NonSegmental Vitiligo.
What interventions are being tested in trial NCT06548360?
The interventions under investigation include: Ruxolitinib Cream (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT06548360?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06548360 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NonSegmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.